Mar 30, 2020   SOURCE: PR NewsWire

Global Antibody Contract Manufacturing Market (2020 to 2030)

DUBLIN, March 30, 2020 The "Antibody Contract Manufacturing Market, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies.

The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

    --  A detailed review of the overall landscape of companies, offering
        contract services for the manufacturing of antibodies, along with
        information on year of establishment, company size, scale of operation
        (preclinical, clinical and commercial), location of headquarters, number
        of manufacturing facilities and location of these facilities, type of
        antibody manufactured (monoclonal antibodies, bispecific antibodies and
        polyclonal antibodies), type of expression systems used (mammalian,
        microbial and others), fill / finish operations and affiliations to
        regulatory agencies.
    --  A competitiveness analysis of key players engaged in this domain,
        featuring an assessment based on their supplier strength (related to the
        experience of a contract manufacturer), and service strength (which
        takes into account the size of service portfolio and scale of
        operation).
    --  A benchmark analysis, highlighting the key focus areas of small,
        mid-sized and large companies, comparing their existing capabilities
        within and beyond their respective (geography-based) peer groups.
    --  An analysis of the various partnerships pertaining to contract
        manufacturing of antibodies, which have been established since 2013,
        based on several parameters, such as the year of agreement, type of
        partnership, project scale and focus therapeutic area.
    --  An analysis of the various expansion initiatives undertaken by service
        providers, in order to augment their respective antibody manufacturing
        capabilities, over the period 2017-2019 (till October), taking into
        consideration parameters, such as year of expansion, type of expansion
        (capacity expansion, facility expansion and new facility), type of
        antibodies manufactured and location of manufacturing facility.
    --  An estimate of the overall, installed capacity for manufacturing
        antibodies based on data reported by industry stakeholders in the public
        domain; it highlights the distribution of available antibody production
        capacity on the basis of company size (small, mid-sized, large and very
        large firms), scale of operation (preclinical, clinical and commercial),
        and key geographical regions (North America, Europe, Asia).
    --  Informed estimates of the annual commercial and clinical demand for
        antibodies, based on various relevant parameters, such as target patient
        population, dosing frequency and dose strength.
    --  Elaborate profiles of the key industry players that offer contract
        manufacturing services at all scales of operation and have more than two
        manufacturing facilities. Each profile features a brief overview of the
        company, information on its service portfolio, details related to its
        manufacturing capabilities and facilities, and an informed future
        outlook.
    --  A case study comparing the key characteristics of large molecule and
        small molecule drugs, along with details on the various steps and
        challenges involved in their respective manufacturing processes.
    --  A discussion on affiliated trends, key drivers and challenges, under a
        SWOT framework, which are likely to impact the industry's evolution,
        including a Harvey ball analysis, highlighting the relative effect of
        each SWOT parameter on the overall pharmaceutical industry.

The report features detailed transcripts of interviews held with the following individuals:

    --  Dietmar Katinger, Chief Executive Officer, Polymun Scientific
    --  David C Cunningham, Director Corporate Development, Goodwin
        Biotechnology
    --  Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVE ANALYSIS

6. COMPANY PROFILES

7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

8. BENCHMARK ANALYSIS

9. PARTNERSHIPS

10. RECENT EXPANSIONS

11. CAPACITY ANALYSIS

12. DEMAND ANALYSIS

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

14. SWOT ANALYSIS

15. FUTURE OF THE ANTIBODY CMO MARKET

16. INTERVIEW TRANSCRIPTS

17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS

18. APPENDIX 2: TABULATED DATA

19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned 

    --  AbbVie Contract Manufacturing
    --  Abcuro
    --  Abdi Ibrahim
    --  A-Bio Pharma
    --  ABL
    --  ABL Bio
    --  Absolute Antibody
    --  Abzena
    --  AC Immune
    --  Acticor Biotech
    --  Actinium Pharmaceuticals
    --  Adagene
    --  Affinita Biotech
    --  Affinity Life Sciences
    --  AGC Biologics
    --  Ajinomoto Althea
    --  Alcami
    --  Aldevron
    --  Alethia Biotherapeutics
    --  Allele Biotechnology & Pharmaceuticals
    --  Alligator Bioscience
    --  Alvotech
    --  Annular Biotech
    --  Antibodies Incorporated
    --  Antibody Production Services (division of Life Science Group)
    --  Arabio
    --  Arcus Biosciences
    --  argenx
    --  ASKA Biotech
    --  ASLAN Pharmaceuticals
    --  AURA Biotechnologies
    --  AutekBio
    --  Avid Bioservices
    --  Avioq
    --  Axcellerate Pharma
    --  Batavia Biosciences
    --  Baxter BioPharma Solutions
    --  Bayer
    --  Baylor Scott & White Research Institute
    --  BeiGene
    --  Bharat Serums and Vaccine
    --  BIBITEC
    --  BINEX
    --  BioInvent International
    --  BioLineRx
    --  Biomay
    --  Biomedical Advanced Research and Development Authority (BARDA)
    --  BiosanaPharma
    --  Biosynergy EUROPE
    --  BioTechnique
    --  Biovian
    --  BioVolutions
    --  BioXcellence (Boehringer Ingelheim)
    --  BJ Bioscience
    --  Brii Biosciences
    --  Bristol-Myers Squibb
    --  Bruker
    --  Calypso Biotech
    --  CANbridge
    --  Capralogics
    --  Catalent
    --  Catalent Biologics
    --  Cell Culture Company
    --  Cell Essentials
    --  Celonic
    --  Center of iPS Cell Research and Application, Kyoto University
    --  Cerbios-Pharma
    --  Changchun High & New Technology Industry
    --  ChemPartner
    --  Chiome Bioscience
    --  CinnaGen
    --  Citryll
    --  CMAB Biopharma
    --  CMC Biologics
    --  Cobra Biologics
    --  Compugen
    --  Cook Pharmica
    --  Creative Biolabs
    --  CytoDyn
    --  Cytovance Biologics
    --  DaTaMabs
    --  Diatec Monoclonals
    --  DM Bio
    --  Dyax
    --  And Many Many More!

For more information about this report visit https://www.researchandmarkets.com/r/ta244f

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-antibody-contract-manufacturing-market-2020-to-2030-301031600.html

SOURCE Research and Markets